Concentration-dependent effects of antimicrobials on staphylococcus aureus toxin-mediated cytokine production from peripheral blood mononuclear cells

Journal of Antimicrobial Chemotherapy

Volumn 67, Issue 1, 2012, Pages 123-129

  Pichereau, Solen ^a,b   Moran, John J M ^a   Hayney, Mary S ^a   Shukla, Sanjay K ^c   Sakoulas, George ^d,e   Rose, Warren E ^a  

^a UNIVERSITY OF WISCONSIN MADISON   (United States)

^b UNIVERSITÉ DE POITIERS   (France)

^c MARSHFIELD CLINIC   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e SHARP MEMORIAL HOSPITAL   (United States)

Author keywords

Community associated MRSA; ELISA; Immune response; Monocytes; Panton Valentine leucocidin

Indexed keywords

ANTIBIOTIC AGENT; AZITHROMYCIN; CLINDAMYCIN; COTRIMOXAZOLE; DAPTOMYCIN; GAMMA INTERFERON; INTERLEUKIN 1BETA; INTERLEUKIN 6; INTERLEUKIN 8; LINEZOLID; PANTON VALENTINE LEUKOCIDIN; STAPHYLOCOCCUS ALPHA TOXIN; STAPHYLOCOCCUS ENTEROTOXIN A; STAPHYLOCOCCUS TOXIN; TIGECYCLINE; TOXIC SHOCK SYNDROME TOXIN 1; TUMOR NECROSIS FACTOR ALPHA; VANCOMYCIN; ANTIINFECTIVE AGENT; BACTERIAL TOXIN; CYTOKINE;

ARTICLE; CYTOKINE PRODUCTION; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IMMUNOMODULATION; IN VITRO STUDY; MAXIMUM PLASMA CONCENTRATION; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; STAPHYLOCOCCUS AUREUS; BLOOD; CELL CULTURE; DRUG EFFECT; IMMUNOLOGY; MONONUCLEAR CELL; SECRETION;

ANTI-INFECTIVE AGENTS; BACTERIAL TOXINS; BLOOD; CELLS, CULTURED; CYTOKINES; HUMANS; LEUKOCYTES, MONONUCLEAR; STAPHYLOCOCCUS AUREUS;

EID: 84856540668     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkr417     Document Type: Article

References (49)

1. Moran GJ, Krishnadasan A, Gorwitz RJ et al. Methicillin-resistant S. aureus infections among patients in the emergency department. N Engl J Med 2006; 355: 666-74.
2. Klevens RM, Morrison MA, Nadle J et al. Invasive methicillin-resistant Staphylococcus aureus infections in the United States. JAMA 2007; 298:1763-71.
3. Adem PV, Montgomery CP, Husain AN et al. Staphylococcus aureus sepsis and the Waterhouse-Friderichsen syndrome in children. N Engl J Med 2005; 353: 1245-51.
4. Kravitz GR, Dries DJ, Peterson ML et al. Purpura fulminans due to Staphylococcus aureus. Clin Infect Dis 2005; 40: 941-7.
5. Miller LG, Perdreau-Remington F, Rieg G et al. Necrotizing fasciitis caused by community-associated methicillin-resistant Staphylococcus aureus in Los Angeles. N Engl J Med 2005; 352: 1445-53.
6. Dinges MM, Orwin PM, Schlievert PM. Exotoxins of Staphylococcus aureus. Clin Microbiol Rev 2000; 13: 16-34.
7. Boyle-Vavra S, Daum RS. Community-acquired methicillin-resistant Staphylococcus aureus: the role of Panton-Valentine leukocidin. Lab Invest 2007; 87: 3-9.
8. Konig B, Prevost G, Piemont Y et al. Effects of Staphylococcus aureus leukocidins on inflammatory mediator release from human granulocytes. J Infect Dis 1995; 171: 607-13.
9. Badiou C, Dumitrescu O, George N et al. Rapid detection of Staphylococcus aureus Panton-Valentine leukocidin in clinical specimens by enzyme-linked immunosorbent assay and immunochromatographic tests. J Clin Microbiol 2010; 48: 1384-90.
10. DeLeo FR, Diep BA, Otto M. Host defense and pathogenesis in Staphylococcus aureus infections. Infect Dis Clin North Am 2009; 23: 17-34.
11. Schlievert PM. Role of superantigens in human disease. J Infect Dis 1993; 167: 997-1002.
12. Libert C, Takahashi N, Cauwels A et al. Response of interleukin-6-deficient mice to tumor necrosis factor-induced metabolic changes and lethality. Eur J Immunol 1994; 24: 2237-42.
13. Xing Z, Gauldie J, Cox G et al. IL-6 is an antiinflammatory cytokine required for controlling local or systemic acute inflammatory responses. J Clin Invest 1998; 101: 311-20.
14. Stevens DL. The toxic shock syndromes. Infect Dis Clin North Am 1996;10: 727-46.
15. Verkaik NJ, Dauwalder O, Antri K et al. Immunogenicity of toxins during Staphylococcus aureus infection. Clin Infect Dis 2010; 50: 61-8.
16. Hayney MS, Buck JM, Muller D. Production of interferon-gamma and interleukin-10 after inactivated hepatitis A immunization.Pharmacotherapy 2003; 23: 431-5.
17. Garcia-Roca P, Mancilla-Ramirez J, Santos-Segura A et al. Linezolid diminishes inflammatory cytokine production from human peripheral blood mononuclear cells. Arch Med Res 2006; 37: 31-5.
18. Varoquaux O, Lajoie D, Gobert C et al. Pharmacokinetics of the trimethoprim-sulphamethoxazole combination in the elderly. Br J Clin Pharmacol 1985; 20: 575-81.
19. Plaisance KI, Drusano GL, Forrest A et al. Pharmacokinetic evaluation of two dosage regimens of clindamycin phosphate. Antimicrob Agents Chemother 1989; 33: 618-20.
20. Dvorchik BH, Brazier D, DeBruin MF et al. Daptomycin pharmacokinetics and safety following administration of escalating doses once daily to healthy subjects. Antimicrob Agents Chemother 2003; 47: 1318-23.
21. Dehghanyar P, Burger C, Zeitlinger M et al. Penetration of linezolid into soft tissues of healthy volunteers after single and multiple doses. Antimicrob Agents Chemother 2005; 49: 2367-71.
22. Muralidharan G, Micalizzi M, Speth J et al. Pharmacokinetics of tigecycline after single and multiple doses in healthy subjects. Antimicrob Agents Chemother 2005; 49: 220-9.
23. Rybak MJ, Lomaestro BM, Rotschafer JC et al. Vancomycin therapeutic guidelines: a summary of consensus recommendations from the Infectious Diseases Society of America, the American Society of Health-System Pharmacists, and the Society of Infectious Diseases Pharmacists. Clin Infect Dis 2009; 49: 325-7.
24. Lina G, Piemont Y, Godail-Gamot F et al. Involvement of Panton-Valentine leukocidin-producing Staphylococcus aureus in primary skin infections and pneumonia. Clin Infect Dis 1999; 29: 1128-32.
25. Francis JS, Doherty MC, Lopatin U et al. Severe community-onset pneumonia in healthy adults caused by methicillin-resistant Staphylococcus aureus carrying the Panton-Valentine leukocidin genes. Clin Infect Dis 2005; 40: 100-7.
26. Cremieux AC, Dumitrescu O, Lina G et al. Panton-Valentine leukocidin enhances the severity of community-associated methicillin-resistant Staphylococcus aureus rabbit osteomyelitis. PLoS One 2009; 4: e7204.
27. Diep BA, Chan L, Tattevin P et al. Polymorphonuclear leukocytes mediate Staphylococcus aureus Panton-Valentine leukocidin-induced lung inflammation and injury. Proc Natl Acad Sci USA 2010; 107: 5587-92.
28. Strandberg KL, Rotschafer JH, Vetter SM et al. Staphylococcal superantigens cause lethal pulmonary disease in rabbits. J Infect Dis 2010; 202: 1690-7.
29. Bartlett AH, Foster TJ, Hayashida A et al. a-Toxin facilitates the generation of CXC chemokine gradients and stimulates neutrophil homing in Staphylococcus aureus pneumonia. J Infect Dis 2008; 198:1529-35.
30. Said-Salim B, Mathema B, Braughton K et al. Differential distribution and expression of Panton-Valentine leucocidin among community-acquired methicillin-resistant Staphylococcus aureus strains. J Clin Microbiol 2005; 43: 3373-9.
31. O'Hara FP, Guex N, Word JM et al. A geographic variant of the Staphylococcus aureus Panton-Valentine leukocidin toxin and the origin of community-associated methicillin-resistant S. aureus USA300.J Infect Dis 2008; 197: 187-94.
32. Villaruz AE, Bubeck Wardenburg J, Khan BA et al. A point mutation in the agr locus rather than expression of the Panton-Valentine leukocidin caused previously reported phenotypes in Staphylococcus aureus pneumonia and gene regulation. J Infect Dis 2009; 200: 724-34.
33. Meyer F, Girardot R, Piemont Y et al. Analysis of the specificity of Panton-Valentine leucocidin and gamma-hemolysin F component binding. Infect Immun 2009; 77: 266-73.
34. Rodvold KA, Gotfried MH, Cwik M et al. Serum, tissue and body fluid concentrations of tigecycline after a single 100 mg dose. J Antimicrob Chemother 2006; 58: 1221-9.
35. Duckworth C, Fisher JF, Carter SA et al. Tissue penetration of clindamycin in diabetic foot infections. J Antimicrob Chemother 1993; 31: 581-4.
36. Conte JE Jr, Golden JA, Kipps J et al. Intrapulmonary pharmacokinetics of linezolid. Antimicrob Agents Chemother 2002; 46: 1475-80.
37. Barbour A, Scaglione F, Derendorf H. Class-dependent relevance of tissue distribution in the interpretation of anti-infective pharmacokinetic/ pharmacodynamic indices. Int J Antimicrob Agents 2010; 35: 431-8.
38. Hirata N, Hiramatsu K, Kishi K et al. Pretreatment of mice with clindamycin improves survival of endotoxic shock by modulating the release of inflammatory cytokines. Antimicrob Agents Chemother 2001;45: 2638-42.
39. Karlstrom A, Boyd KL, English BK et al. Treatment with protein synthesis inhibitors improves outcomes of secondary bacterial pneumonia after influenza. J Infect Dis 2009; 199: 311-9.
40. Stevens DL, Bryant AE, Hackett SP. Antibiotic effects on bacterial viability, toxin production, and host response. Clin Infect Dis 1995; 20 Suppl 2: S154-7.
41. Lambers C, Burian B, Binder P et al. Early immunomodulatory effects of linezolid in a human whole blood endotoxin model. Int J Clin Pharmacol Ther 2010; 48: 419-24.
42. Tamaoki J, Kadota J, Takizawa H. Clinical implications of the immunomodulatory effects of macrolides. Am J Med 2004; 117 Suppl 9A: 5S-11S.
43. Meyer M, Huaux F, Gavilanes X et al. Azithromycin reduces exaggerated cytokine production by M1 alveolar macrophages in cystic fibrosis. Am J Respir Cell Mol Biol 2009; 41: 590-602.
44. Tsai WC, Hershenson MB, Zhou Y et al. Azithromycin increases survival and reduces lung inflammation in cystic fibrosis mice. Inflamm Res 2009; 58: 491-501.
45. Dumitrescu O, Badiou C, Bes M et al. Effect of antibiotics, alone and in combination, on Panton-Valentine leukocidin production by a Staphylococcus aureus reference strain. ClinMicrobiol Infect 2008; 14: 384-8.
46. Tigacil Prescribing Information. New York, NY, USA: Pfizer Inc., 2007.
47. Cai Y, Wang R, Liang B et al. Systematic review and meta-analysis of the effectiveness and safety of tigecycline for treatment of infectious disease. Antimicrob Agents Chemother 2011; 55: 1162-72.
48. Sakoulas G, Rose W. Evaluation of host inflammatory responses and their relationship to clinical presentation in patients with Staphylococcus aureus bacteremia. In: Abstracts of the Forty-eighth Annual Meeting of the Infectious Diseases Society of America, Vancouver, BC, 2010. Abstract 1158. Infectious Diseases Society of America, Arlington, VA, USA.
49. Meisel C, Schefold JC, Pschowski R et al. Granulocyte-macrophage colony-stimulating factor to reverse sepsis-associated immuno suppression: a double-blind, randomized, placebo-controlled multicenter trial. Am J Respir Crit Care Med 2009; 180: 640-8.